{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:39:41Z","timestamp":1791103181694,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases, NIH","doi-asserted-by":"crossref","award":["R01 AI 70955"],"award-info":[{"award-number":["R01 AI 70955"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases, NIH","doi-asserted-by":"crossref","award":["AI 99125"],"award-info":[{"award-number":["AI 99125"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases, NIH","doi-asserted-by":"crossref","award":["AI 46464"],"award-info":[{"award-number":["AI 46464"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases, NIH","doi-asserted-by":"crossref","award":["AI 82263"],"award-info":[{"award-number":["AI 82263"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources, NIH","doi-asserted-by":"crossref","award":["C06 RR 16226"],"award-info":[{"award-number":["C06 RR 16226"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.vaccine.2013.08.099","type":"journal-article","created":{"date-parts":[[2013,9,11]],"date-time":"2013-09-11T11:01:26Z","timestamp":1378897286000},"page":"5451-5457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice"],"prefix":"10.1016","volume":"31","author":[{"given":"Raffaella","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan M.","family":"Granoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T.","family":"Beernink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2013.08.099_bib0095","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/INF.0b013e318282942f","article-title":"Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease","volume":"32","author":"Granoff","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"10.1016\/j.vaccine.2013.08.099_bib0010","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/INF.0b013e31826327e4","article-title":"Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18\u201336 months: a phase 1 randomized-controlled clinical trial","volume":"31","author":"Marshall","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"10.1016\/j.vaccine.2013.08.099_bib0015","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Richmond","year":"2012","journal-title":"The Lancet Infectious Diseases"},{"issue":"6","key":"10.1016\/j.vaccine.2013.08.099_bib0020","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.vaccine.2013.08.099_bib0025","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"issue":"37","key":"10.1016\/j.vaccine.2013.08.099_bib0030","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2013.08.099_bib0035","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1086\/528994","article-title":"Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen","volume":"197","author":"Welsch","year":"2008","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2013.08.099_bib0040","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1128\/IAI.05182-11","article-title":"Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding","volume":"79","author":"Giuntini","year":"2011","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2013.08.099_bib0085","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/infdis\/jit239","article-title":"Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines","volume":"208","author":"Konar","year":"2013","journal-title":"J Infect Dis"},{"issue":"Suppl. 8","key":"10.1016\/j.vaccine.2013.08.099_bib0050","doi-asserted-by":"crossref","first-page":"I113","DOI":"10.1016\/j.vaccine.2008.11.058","article-title":"Microbial complement inhibitors as vaccines","volume":"26","author":"Meri","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2013.08.099_bib0055","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/IAI.01191-08","article-title":"Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera","volume":"77","author":"Granoff","year":"2009","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2013.08.099_bib0060","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.4049\/jimmunol.1003470","article-title":"A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination","volume":"186","author":"Beernink","year":"2011","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2013.08.099_bib0065","doi-asserted-by":"crossref","first-page":"e1002688","DOI":"10.1371\/journal.ppat.1002688","article-title":"The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein","volume":"8","author":"Beernink","year":"2012","journal-title":"PLoS Pathog"},{"issue":"10","key":"10.1016\/j.vaccine.2013.08.099_bib0125","doi-asserted-by":"crossref","first-page":"e1002981","DOI":"10.1371\/journal.ppat.1002981","article-title":"Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules","volume":"8","author":"Johnson","year":"2012","journal-title":"PLoS Pathog"},{"issue":"11","key":"10.1016\/j.vaccine.2013.08.099_bib0160","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1167\/iovs.09-4457","article-title":"Transgenic mice expressing variants of complement factor H develop AMD-like retinal findings","volume":"51","author":"Ufret-Vincenty","year":"2010","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"8","key":"10.1016\/j.vaccine.2013.08.099_bib0080","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1128\/IAI.00103-12","article-title":"Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H","volume":"80","author":"Pajon","year":"2012","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2013.08.099_bib0165","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1423-0410.2006.00884.x","article-title":"Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development","volume":"92","author":"Heger","year":"2007","journal-title":"Vox sanguinis"},{"issue":"5","key":"10.1016\/j.vaccine.2013.08.099_bib0170","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1167\/iovs.07-1523","article-title":"Fernandez-Robredo P, et al. Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degeneration","volume":"49","author":"Hakobyan","year":"2008","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"12","key":"10.1016\/j.vaccine.2013.08.099_bib0175","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1167\/iovs.09-3928","article-title":"Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes","volume":"50","author":"Reynolds","year":"2009","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"Pt. 6","key":"10.1016\/j.vaccine.2013.08.099_bib0180","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/brain\/awq085","article-title":"Complement regulator factor H as a serum biomarker of multiple sclerosis disease state","volume":"133","author":"Ingram","year":"2010","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.vaccine.2013.08.099_bib0100","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1128\/IAI.00367-08","article-title":"Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor H-binding protein","volume":"76","author":"Beernink","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.08.099_bib0185","series-title":"The Proteomics Protocols Handbook","first-page":"571","article-title":"Protein identification and analysis tools on the ExPASy server","author":"Gasteiger","year":"2005"},{"issue":"9","key":"10.1016\/j.vaccine.2013.08.099_bib0110","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1086\/597806","article-title":"Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa","volume":"199","author":"Beernink","year":"2009","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2013.08.099_bib0115","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1128\/CVI.00097-06","article-title":"Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate","volume":"13","author":"Beernink","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2013.08.099_bib0120","doi-asserted-by":"crossref","first-page":"e1302","DOI":"10.1371\/journal.pntd.0001302","article-title":"Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development","volume":"5","author":"Pajon","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2013.08.099_bib0190","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.1074\/jbc.M808831200","article-title":"Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086","volume":"284","author":"Mascioni","year":"2009","journal-title":"J Biol Chem"},{"issue":"8\u20139","key":"10.1016\/j.vaccine.2013.08.099_bib0130","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.molimm.2009.02.021","article-title":"A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups","volume":"46","author":"Beernink","year":"2009","journal-title":"Mol Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2013.08.099_bib0075","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1128\/CVI.00260-13","article-title":"Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?","volume":"20","author":"Granoff","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2013.08.099_bib0135","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.vaccine.2009.12.027","article-title":"Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates","volume":"28","author":"Pajon","year":"2010","journal-title":"Vaccine"},{"issue":"29\u201330","key":"10.1016\/j.vaccine.2013.08.099_bib0145","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1016\/j.vaccine.2011.04.092","article-title":"Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2013.08.099_bib0150","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2013.08.099_bib0155","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.4049\/jimmunol.160.10.5028","article-title":"Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid","volume":"160","author":"Granoff","year":"1998","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13012115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13012115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T13:45:26Z","timestamp":1688478326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13012115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":32,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0264410X13012115"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.08.099","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.08.099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}